PALVELLA THERAPEUTICS, INC. quarterly report, Q2 FY2017

Business context and reporting period

This is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2017. The request metadata names Palvella Therapeutics, but the filing identifies Pieris as the registrant.

Pieris is a clinical-stage biotechnology company developing Anticalin-based medicines, including immuno-oncology candidates PRS-343 and PRS-332, anemia candidate PRS-080, and inhaled asthma candidate PRS-060. It had no product sales; revenue came from collaborations, licenses, research services, and grants.

Financial performance and position

Q2 revenue rose 73% year over year, primarily reflecting revenue under the new Servier and AstraZeneca collaborations. First-half revenue increased 38%. Losses widened as operating expenses rose; Q2 G&A included $1.8 million of AstraZeneca transaction fees. Q2 and first-half other expense included approximately $1.4 million of net foreign-currency transaction losses. First-half income tax expense was $0.8 million, related to Australian taxable income associated with AstraZeneca.

At June 30, cash was $50.3 million, versus $29.4 million at year-end 2016. Total assets were $106.0 million, total liabilities $96.6 million, and stockholders’ equity $9.3 million. Deferred revenue totaled $85.6 million, including current and non-current portions, reflecting collaboration payments not yet recognized as revenue. Accounts receivable was $48.5 million. The filing reports no material debt balance; it lists $42,862 of other long-term liabilities.

For the six months, operating cash flow was positive $19.3 million, compared with negative $4.1 million in 2016. This reflected collaboration-related deferred revenue growth, partly offset by a $46.5 million increase in accounts receivable; it should not be read as operating profitability. Investing cash outflow was $0.8 million, financing cash inflow $1.5 million, and cash increased by $21.0 million. Gross margins are not meaningfully presented for this development-stage business.

Material changes and collaboration developments

• AstraZeneca: The collaboration covers PRS-060 and four additional respiratory programs. Pieris received a $45 million upfront payment in July 2017, after quarter-end; an additional $12.5 million is tied to initiation of the PRS-060 Phase I trial. The company reported potential research, development, commercial, and sales milestones of up to approximately $2.1 billion, plus royalties or potential margin sharing. The Phase I trial was planned to begin in Q4 2017.
• Servier: The January 2017 agreement covers five initial bispecific programs, led by PRS-332. Pieris received a non-refundable upfront payment of €30 million (approximately $32 million). It reported potential milestones of up to €569 million for research, development, and commercial events and €515 million for sales events, plus royalties. The parties share costs for selected co-development programs.
• ASKA: ASKA paid a $2.75 million option fee relating to PRS-080 rights in Japan and certain other Asian territories. No revenue had been recognized by June 30; the fee was deferred pending delivery of Phase IIa study results. ASKA then has an evaluation period and may exercise its option.
• Roche: The research program was amended to extend its initial period to January 1, 2018, with an option to extend through August 31, 2018.

Outlook, risks, and unusual items

Management expected substantial losses to continue for several years and did not expect product-sales revenue for the foreseeable future. It stated that cash on hand at June 30, together with the $45 million AstraZeneca payment received in July, was expected to fund the current operating plan for at least 12 months from the filing date. Management also said additional capital may be required; there is no assurance it can be obtained on acceptable terms. Financing shortfalls could delay, reduce, or eliminate programs.

Clinical and regulatory outcomes remain uncertain. The company planned to initiate a PRS-080 Phase IIa study in Q3 2017, subject to regulatory approvals; it was preparing to begin PRS-343 patient dosing in a Phase I study. Collaboration revenue and milestone timing depend on performance, development progress, and partner decisions. Other disclosed risks include foreign-exchange exposure, reliance on third parties, potential dilution or financing constraints, and the possibility that partners terminate agreements under their contractual rights. The company reported no material change to its previously disclosed risk factors, no off-balance-sheet arrangements, and no specific material legal proceeding in the supplied text.

Other notable items: Pieris appointed Allan Reine as CFO on August 9, 2017, after quarter-end. Management assessed internal control over financial reporting as effective at June 30, 2017. The company was evaluating the impact of the forthcoming revenue-recognition and lease accounting standards.

Important facts for investors to verify

• Confirm the timing and conditions for the $12.5 million AstraZeneca Phase I initiation payment and whether the planned trial milestones were met.
• Track cash burn and runway using updated cash, receivables, deferred revenue, and collaboration receipts—not operating cash flow alone.
• Review clinical and regulatory progress for PRS-343, PRS-332, PRS-080, and PRS-060, including whether planned study starts occurred.
• Assess how collaboration consideration is allocated and recognized over time, and the assumptions behind deferred revenue and potential milestone revenue.
• Monitor future financing needs, foreign-currency effects, collaboration cost-sharing, and any partner termination or development decisions.